Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Jul. 4—MORGANTOWN — The tangled world of generic pharmaceuticals took another twist last week, as Mylan Pharmaceuticals filed suit in federal court against Israel-based Teva, alleging Teva illegally ...

Copaxone (glatiramer) is a prescription drug used to treat certain types of multiple sclerosis (MS). Copaxone’s cost may depend on factors such as your dosage, whether you have health insurance, and ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

The Commission opened proceedings against Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe B.V. in March 2021 under Article 102 TFEU, following dawn raids in October 2019; a ...

(Reuters) - The U.S. Food and Drug Administration approved on Thursday the first generic version of Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The generic drug ...

Johnson & Johnson’s Momenta Pharmaceuticals unit is crying patent infringement against Mylan—now Viatris—plus two of the generics maker’s Indian manufacturing partners, according to a new lawsuit. But ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update, which also ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.